News

Under terms of the agreement, unanimously approved by both companies’ boards of directors, TorreyPines stockholders would own approximately 58% of the combined company and Axonyx stockholders would own

Remicade was developed by Johnson & Johnson unit Centocor but is distributed in Canada by Schering-Plough’s Canadian subsidiary. Research has shown that the majority of patients treated with

The primary purposes of this clinical trial were to assess the safety and tolerability of DN-101 in combination with Sanofi-Aventis’ Taxotere (docetaxel) and to evaluate the objective tumor

PHX1149 is a potent and selective inhibitor of DPP4, a serine protease that has emerged as an important target for the treatment of type 2 diabetes. Inhibiting DPP4

Hollis-Eden’s goal in this trial will be to establish the safety of Neumune in this population, and to help identify the optimal patient subsets for further study in

The primary goal of the study is to compare the recurrence-free survival at 15 months in patients treated with either GI-4000 or placebo, in combination with adjuvant gemcitabine

AZD6244 is a selective MEK inhibitor that was in-licensed by AstraZeneca from Array in December 2003. AstraZeneca expects the first patient to be enrolled in this melanoma study

Cutaneous T-cell-lymphoma (CTCL), a type of non-Hodgkin’s lymphoma, is a slow-growing form of cancer in which some of the body’s white blood cells known as T-lymphocytes or T-cells

The study included in the investigational new drug application is designed to evaluate the pharmacokinetic parameters, appetite, food intake and safety of various dosing regimens of PYY nasal